10.46
+0.51(+5.13%)
Currency In USD
| Previous Close | 9.95 |
| Open | 9.95 |
| Day High | 10.59 |
| Day Low | 9.79 |
| 52-Week High | 14.27 |
| 52-Week Low | 4.93 |
| Volume | 116,949 |
| Average Volume | 224,883 |
| Market Cap | 399.77M |
| PE | -4.07 |
| EPS | -2.57 |
| Moving Average 50 Days | 9.58 |
| Moving Average 200 Days | 7.57 |
| Change | 0.51 |
If you invested $1000 in Entrada Therapeutics, Inc. (TRDA) since IPO date, it would be worth $436.74 as of January 14, 2026 at a share price of $10.46. Whereas If you bought $1000 worth of Entrada Therapeutics, Inc. (TRDA) shares 3 years ago, it would be worth $754.15 as of January 14, 2026 at a share price of $10.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, Ja
Entrada Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Oct 28, 2025 11:00 AM GMT
BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Jefferies Global Healthcare Conference in LondonDipal Doshi, Chief Executive Offi